An exceptional response to 177LuPSMA undermined by neuroendocrine transformation

Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC).177Lu-prostate specific membrane antigen (-PSMA) is an emerging iphone 13 pro max price florida alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation do not express PSMA and are not affected by this treatment.This case highlights equi-jec 6 an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver.